Hostname: page-component-8448b6f56d-m8qmq Total loading time: 0 Render date: 2024-04-19T07:14:05.224Z Has data issue: false hasContentIssue false
  • English
  • Français

Serotoninergic antidepressants positively affect platelet ADAM10 expression in patients with Alzheimer's disease

Published online by Cambridge University Press:  11 November 2015

Otávio Augusto Fernandes Marques Bianco ,
Patrícia Regina Manzine ,
Carla Manuela Crispim Nascimento ,
Francisco Assis Carvalho Vale ,
Sofia Cristina Iost Pavarini  and
Márcia Regina Cominetti
Otávio Augusto Fernandes Marques Bianco
Affiliation:
Department of Gerontology, Federal University of São Carlos (UFSCar), São Carlos, SP, Brazil
Patrícia Regina Manzine
Affiliation:
Department of Gerontology, Federal University of São Carlos (UFSCar), São Carlos, SP, Brazil
Carla Manuela Crispim Nascimento
Affiliation:
Department of Gerontology, Federal University of São Carlos (UFSCar), São Carlos, SP, Brazil
Francisco Assis Carvalho Vale
Affiliation:
Department of Medicine, Federal University of São Carlos (UFSCar), São Carlos, SP, Brazil
Sofia Cristina Iost Pavarini
Affiliation:
Department of Gerontology, Federal University of São Carlos (UFSCar), São Carlos, SP, Brazil
Márcia Regina Cominetti*
Affiliation:
Department of Gerontology, Federal University of São Carlos (UFSCar), São Carlos, SP, Brazil
*
Correspondence should be addressed to: Márcia Regina Cominetti, Departamento de Gerontologia, Universidade Federal de São Carlos, Rodovia Washington Luís, Km 235, São Carlos, SP, 13565–905, Brazil. Phone: +55-16-3306 6663; Fax: +55-16-3351-9628. Email: mcominetti@ufscar.br.
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Studies have demonstrated a decreased platelet ADAM10 expression in patients with Alzheimer's Disease (AD), classifying this protein as a blood-based AD biomarker. About 50% of the patients with AD are diagnosed with depression, which is commonly treated with tricyclic and tetracyclic antidepressants, monoaminoxidade (MAO) inhibitors and, more preferably, with selective serotonin reuptake inhibitors (SSRIs). Considering that a large proportion of patients with AD takes antidepressant medications during the course of the disease we investigated the influence of this medication on the expression of platelet ADAM10, which is considered the main α-secretase preventing beta-amyloid (βA) formation.

Methods:

Blood was collected for protein extraction from platelets. ADAM10 was analyzed by using western blotting and reactive bands were measured using β-actin as endogenous control.

Results:

Platelet ADAM10 protein expression in patients with AD was positively influenced by serotoninergic medication.

Conclusion:

More studies on the positive effects of serotonergic antidepressants on ADAM10 platelet expression should be performed in order to understand its biological mechanisms and to verify whether these effects are reflected in the central nervous system. This work represents an important advance for the study of AD biomarkers, as well as for more effective pharmacological treatment of patients with AD and associated depression.

Keywords

antidepressant drugsAlzheimer’s diseasebiomarkersdementiadepressionhuman ADAM10 protein
Type
Research Article
Information
International Psychogeriatrics , Volume 28 , Issue 6 , June 2016 , pp. 939 - 944
Copyright
Copyright © International Psychogeriatric Association 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Arjona, A. A., Pooler, A. M., Lee, R. K. and Wurtman, R. J. (2002). Effect of a 5-HT(2C) serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs. Brain Research, 951, 135–140.Google Scholar
Bandyopadhyay, S., Goldstein, L. E., Lahiri, D. K. and Rogers, J. T. (2007). Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer's disease. Current Medicinal Chemistry, 14, 2848–2864.Google Scholar
Bernstein, H. G., Steiner, J., Bogerts, B., Stricker, R. and Reiser, G. (2014). Nardilysin, ADAM10, and Alzheimer's disease: of mice and men. Neurobiol Aging, 35, e1.Google Scholar
Bockaert, J., Claeysen, S., Compan, V. and Dumuis, A. (2011). 5-HT(4) receptors, a place in the sun: act two. Current Opinion in Pharmacology, 11, 87–93.Google Scholar
Brucki, S. M., Nitrini, R., Caramelli, P., Bertolucci, P. H. and Okamoto, I. H. (2003). Suggestions for utilization of the mini-mental state examination in Brazil. Arquives of Neuropsiquiatry, 61, 777–781.CrossRefGoogle ScholarPubMed
Caraci, F., Copani, A., Nicoletti, F. and Drago, F. (2010). Depression and Alzheimer's disease: neurobiological links and common pharmacological targets. European Journal of Pharmacology, 626, 64–71.CrossRefGoogle ScholarPubMed
Chi, S., Wang, C., Jiang, T., Zhu, X. C., Yu, J. T. and Tan, L. (2015). The prevalence of depression in Alzheimer's disease: a systematic review and meta-analysis. Current Alzheimer Research, 12, 189–198.CrossRefGoogle ScholarPubMed
Cirrito, J. R. et al. (2011). Serotonin signaling is associated with lower amyloid-beta levels and plaques in transgenic mice and humans. Proceedings of Natural Academy of Science USA, 108, 14968–14973.Google Scholar
Cochet, M. et al. (2013). 5-HT4 receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10. ACS Chemical Neuroscience, 4, 130–140.Google Scholar
Colciaghi, F. et al. (2002). [alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients. Molecular Medicine, 8, 67–74.CrossRefGoogle ScholarPubMed
Colciaghi, F. et al. (2004). Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology, 62, 498–501.CrossRefGoogle ScholarPubMed
Fahrenholz, F. (2010). The close link between retinoid signalling and the alpha-secretase ADAM10 and its potential for treating Alzheimer's disease (commentary on Jarvis et al.). European Journal of Neuroscience, 32, 1245.Google Scholar
Hardy, J. and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297, 353–356.Google Scholar
Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680–685.Google Scholar
Manzine, P. R., Barham, E. J., Vale, F. A., Selistre-de-Araujo, H. S., Pavarini, S. C. and Cominetti, M. R. (2014). Platelet a disintegrin and metallopeptidase 10 expression correlates with clock drawing test scores in Alzheimer's disease. International Journal of Geriatric Psychiatry, 29, 414–420.Google Scholar
Manzine, P. R., Barham, E. J., Vale Fde, A., Selistre-de-Araujo, H. S., Iost Pavarini, S. C. and Cominetti, M. R. (2013a). Correlation between mini-mental state examination and platelet ADAM10 expression in Alzheimer's disease. Journal of Alzheimers Disease, 36, 253–260.Google Scholar
Manzine, P. R. et al. (2013b). ADAM10 as a biomarker for Alzheimer's disease: a study with Brazilian elderly. Dementia and Geriatriatic Cognitive Disorders, 35, 58–66.Google Scholar
Manzine, P. R. et al. (2015). ADAM10 gene expression in the blood cells of Alzheimer's disease patients and mild cognitive impairment subjects. Biomarkers, 20, 196–201.Google Scholar
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939–944.Google Scholar
Montano, M. B. and Ramos, L. R. (2005). [Validity of the Portuguese version of Clinical Dementia Rating]. Revista de Saude Publica, 39, 912–917.Google Scholar
Nelson, R. L. et al. (2007). Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Experimental Neurology, 205, 166–176.Google Scholar
Postina, R. (2012). Activation of alpha-secretase cleavage. Journal of Neurochemistry, 120 (Suppl. 1), 46–54.CrossRefGoogle ScholarPubMed
Rozzini, L. et al. (2010). Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors. International Psychogeriatrics, 22, 114–119.Google Scholar
Shen, F. et al. (2011). 5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment. Neuropharmacology, 61, 69–79.Google Scholar
Thathiah, A. and De Strooper, B. (2011). The role of G protein-coupled receptors in the pathology of Alzheimer's disease. Nature Reviews Neuroscience, 12, 73–87.Google Scholar